in five levodopa ( l-dopa ) -treated patients with parkinson 's disease with severe fluctuations of motor performance , plasma l-dopa as well as dopamine levels were measured during 2 days , first under optimal standard l-dopa with peripheral decarboxylase inhibitor ( pdi ) and then after a dose adjustment period using slow-release l-dopa/benserazide ( madopar hbs ) in an open inpatient trial .
C0030567
parkinson 's disease
C0023570
l-dopa